Adjuvant Chemotherapy in Patients With Pancreatic Adenocarcinoma After Multiagent Neoadjuvant Chemotherapy

Is there a survival benefit of adjuvant chemotherapy in patients with pancreatic adenocarcinoma after multiagent neoadjuvant chemotherapy?In this cohort study of 888 propensity score–matched patients who received multiagent neoadjuvant therapy, patients who received adjuvant chemotherapy survived significantly longer than patients who did not receive adjuvant chemotherapy . The benefit varied by age, pathological T category, and tumor differentiation.

Patients were excluded if they had clinical or pathological stage IV disease or died within 90 days of their operation.All included patients received NAC and underwent resection for primary PDAC. Some patients received adjuvant chemotherapy.The main outcome was the OS of patients who received AC vs those who did not . Interactions between pathological findings and AC were investigated in separate multivariable Cox regression models.

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Innovative precision oncology enabled by micro-organospheres derived from patientsInnovative precision oncology enabled by micro-organospheres derived from patients 3DCulture CellCulture Oncology TissueCulture precisiononcology microfluidics tumorsphere CellStemCell
Source: NewsMedical - 🏆 19. / 71 Read more »

What is the prevalence of pulmonary tissue injury among hospitalized COVID-19 patients?Researchers identified risk factors for and the prevalence of persistent pulmonary tissue alterations among hospitalized coronavirus disease 2019 (COVID-19) patients.
Source: NewsMedical - 🏆 19. / 71 Read more »